New autoimmune disorder development after immune reconstitution therapy for multiple sclerosis

Area of Science:

• Neurology
• Immunology
• Clinical Medicine

Background:

• Immune reconstitution therapy (IRT) offers a highly effective treatment for multiple sclerosis (MS).
• The potential for developing secondary autoimmune disorders (ADs) after certain IRTs requires further investigation.
• Understanding the incidence and characteristics of post-IRT ADs is crucial for patient management.

Purpose of the Study:

• To evaluate the incidence of new AD development in MS patients following IRT.
• To characterize the types of ADs that emerge after IRT.
• To determine the time to onset for these secondary ADs.

Main Methods:

• Retrospective analysis of 179 relapsing MS patients treated with IRT over ten years.
• Categorization of IRT into autologous hematopoietic stem cell transplantation (AHSCT), alemtuzumab (ALE), and cladribine (CLA).
• Monitoring and documentation of new AD development and time to onset post-treatment.

Main Results:

• Overall AD incidence varied by IRT: 16.2% after AHSCT, 42.1% after ALE, and 1.6% after CLA.
• ADs emerged sooner after alemtuzumab but later after AHSCT (excluding cytopenias).
• Alemtuzumab and AHSCT were associated with a higher risk of secondary ADs in MS patients.

Conclusions:

• Neurologists must remain vigilant for secondary AD development in MS patients treated with alemtuzumab and AHSCT.
• The risk and timing of ADs differ significantly among various IRT modalities.
• Further research into the mechanisms and management of post-IRT ADs is warranted.